loperamide chronic IBS-D
Selected indexed studies
- Chronic, Noninfectious Diarrhea: A Review. (JAMA, 2026) [PMID:41770539]
- Novel pharmacological therapies for irritable bowel syndrome. (Expert Rev Gastroenterol Hepatol, 2016) [PMID:26907518]
- An Evidence-based Approach to Therapy in IBS-D: A Case Study Compendium. (Gastroenterol Hepatol (N Y), 2010) [PMID:22570639]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Chronic, Noninfectious Diarrhea: A Review. (2026) pubmed
- Novel pharmacological therapies for irritable bowel syndrome. (2016) pubmed
- An Evidence-based Approach to Therapy in IBS-D: A Case Study Compendium. (2010) pubmed
- Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide. (2021) pubmed
- [Chronic, non-infectious diarrhea: diagnostics and therapy]. (2016) pubmed
- Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS. (2016) pubmed
- Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. (2020) pubmed